Lun Zeng

Guangdong Xiangxue Precision Medical Technology Co., Ltd. engages in TCR-based therapies for cancer. It provides research and development services, including large scale GMP grade lentivirus production, target identification and lead optimization, efficacy validation and safety testing in cell lines and animal models, clinical trial development, and market entry planning. The company was founded on November 12, 2015 and is headquartered in Guangzhou, China.

Part of Gortune Investment Co., Ltd., Guangzhou Xiangxue Bio-medical Eng Co., Ltd. is a bio medical company. The company is based in Guangzhou, China. Guangzhou Xiangxue Bio-medical Eng Co. was acquired by Yuemin Investment Guangzhou Financial Invt Co., Ltd. from Xiangxue Pharmaceutical Co., Ltd. on December 06, 2021 for $2.83 million. The Chinese company was founded in 2000. The CEO is Lun Zeng.